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journal homepage: www.elsevier .com/locate/rmedLETTER TO THE EDITORPreventing COPD exacerbations with
macrolides: A review and budget impact
analysis e Author response to letter to the
EditorBased on a review of the literature and a budget impact
analysis, our article corroborated the long-term effective-
ness and safety of macrolides in chronic obstructive pul-
monary disease (COPD) patients and demonstrated that
preventing COPD exacerbations with azithromycin saves
money in Belgium [1]. In their letter to the editor, Amigo
and Soler argue that such a strategy is also cost-effective
[2]. This is likely to be the case given that long-term
treatment with macrolides reduces the number of exacer-
bations, thereby generating savings to the health care
payer as a result of a reduction in exacerbation-related
hospitalisations. However, there is a need for a full eco-
nomic evaluation to explore the cost-effectiveness of long-
term treatment with macrolides that also takes account of
a number of factors which have received little attention to
date, i.e. the possible impact of long-term treatment with
macrolides on adverse events, resistance levels, use of
other medication (e.g. inhaled corticosteroids), and physi-
cian visits in ambulatory care [1].
Amigo and Soler state that long-term treatment of COPD
patients with macrolides should be set in a respiratory day
hospital as opposed to conventional hospitalisation [2].
They found that long-term treatment with macrolides in
respiratory day hospital can diminish the number of
exacerbation-related hospitalisations by 30%. In the pivotal
trial by Albert et al., long-term treatment with azi-
thromycin reduced the number of hospitalisations by 11%e
28% as compared to usual care, depending on the GOLD
stage of patients [3]. More research is needed to identify
the most cost-effective setting for providing long-term
treatment with macrolides to COPD patients.
As stated by Amigo and Soler, one remaining issue is
which COPD patients are candidates for long-term treat-
ment with macrolides [2]. In our budget impact analysis,
patient selection included the subset of patients in GOLD
stage II who experience many exacerbations under usualDOI of original article: http://dx.doi.org/10.1016/
j.rmed.2013.04.025.
http://dx.doi.org/10.1016/j.rmed.2014.04.013
0954-6111/ª 2014 Elsevier Ltd. All rights reserved.care and patients in GOLD stages III and IV [1]. This patient
selection is broader than the proposal of Amigo and Soler to
restrict treatment to severe COPD patients who continue to
experience exacerbations despite usual care. When patient
selection in our budget impact analysis was restricted to
patients with a history of frequent COPD exacerbations,
long-term treatment with azithromycin still produced sav-
ings albeit smaller savings than in the base case analysis.
In conclusion, although there are clear indications that
long-term treatment of COPD patients with macrolides is
cost-effective, a future economic evaluation needs to
establish the health care setting and the type of COPD
patients for which long-term treatment with macrolides is
cost-effective.
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